LabViews Newsletter October 2008
Biomarkers Europe
Nov. 10 - 11, 2008
InterContinental Wien
Vienna, Austria
DIA 3rd Annual Cardiac Safety Conference
Dec. 4 - 5, 2008
Hotel Hilton
Barcelona, Spain
CBI 3rd Annual Cardiac Safety Assessment Summit
Jan. 12 - 12, 2009
Sheraton Premiere
Vienna, VA
IIR 7th Annual Partnering with Central Labs, EDC and Imaging Labs
Jan. 26 - 28, 2009
Red Rock Resort
Las Vegas, NV
Biomarker Assay Development
Jan. 26 - 28, 2009
Westin San Diego
San Diego, CA
CBI 6th Annual Medical Imaging for Clinical Trials
Feb. 26 - 27, 2009
Washington, DC
Contact Us
Click here to contact Marissa Shapiro, assistant editor.
Click here to learn about direct mail opportunities.
Click here to learn about reprints of Applied Clinical Trials.
ADVERTISMENT
i3
i3 is one of the world’s leading providers of specialized pharmaceutical services, delivering integrated scientific strategies and solutions throughout the product lifecycle. At any point from development to market, anywhere you need to be, we deliver specialization and scientific depth for your most intricate challenges. Look to us to see all the possibilities.
Learn how Cardiac Safety strategies can protect drug research program. Web-Seminar: “Leveraging a Multiphase QT Strategy to Expedite Development and Reduce Investment Risk” on Wednesday, November 5th, 2008, from 11:00am - 12:30pm EST.
For 25 years, IBT Laboratories has provided the broadest range of allergy and immunological tests available from a single provider to complement pharmaceutical product development.
EXPeRT® ePRO – Simplified. Delivered. Guaranteed. Trust your patient reported outcomes with eRT, an industry-leading clinical technology provider.
You are subscribed to apct_enews_labviews as [email protected] To unsubscribe from this list click here.To ensure delivery to your Inbox, please add [email protected] to your address book. If you need help doing this, click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
